Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD3974
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD3974 is an experimental oral drug candidate currently being developed by AstraZeneca. It is in the early stages of clinical evaluation, specifically Phase I, where it is being tested in healthy volunteers to determine its safety, tolerability, and pharmacokinetic profile. The clinical program includes dedicated cohorts for participants of Japanese and Chinese descent, indicating a strategy for global development. As of its current development status, AstraZeneca has not publicly disclosed the drug's specific biological target, mechanism of action, or the primary therapeutic indications it is intended to treat.
Beyond the preview
Go deeper on AZD3974.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD3974.